Key result
Rofecoxib increases major cardiovascular events ~92% in the APPROVe trial.
Answers are grounded in this paper and cite their sources.
Approximately six years after the cyclooxygenase-2 (COX-2) inhibitors were approved for use in the United States, the results of three randomized, placebo-controlled trials provide new evidence about the cardiovascular risks of rofecoxib, celecoxib, and valdecoxib.13 The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial, a study of patients with a history of colorectal adenomas, was stopped early because rofecoxib doubled the risk of major cardiovascular events (relative risk, 1.92; 95 percent confidence interval, 1.19 to 3.11). These findings confirmed the increased risk of myocardial infarction previously seen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial4 and some observational studies.5 The . . .
No takes yet. Share an insight, caveat, or question.
Psaty et al. (2005) conducted an editorial in Colorectal adenomas. Rofecoxib vs. Placebo was evaluated on Major cardiovascular events (RR 1.92, 95% CI 1.19-3.11). Rofecoxib doubled the risk of major cardiovascular events in the APPROVe trial, confirming the increased cardiovascular risk of COX-2 inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: